How should a patient with G6PD deficiency presenting with bilateral knee pain be evaluated and managed?

Evaluation and Management of G6PD Deficiency with Bilateral Knee Pain

A patient with G6PD deficiency presenting with bilateral knee pain requires immediate evaluation for hemolysis-related complications, particularly rhabdomyolysis or hemolytic crisis, while simultaneously assessing for standard musculoskeletal causes of bilateral knee pain.

Initial Diagnostic Approach

Rule Out G6PD-Related Complications First

The bilateral presentation demands urgent consideration of systemic G6PD-related complications:

• Check complete blood count with differential to assess for hemolytic anemia (hemoglobin, hematocrit, reticulocyte count) 1
• Obtain comprehensive metabolic panel including creatinine kinase (CK) to evaluate for rhabdomyolysis, which can present as bilateral muscle/joint pain in G6PD deficiency 2
• Assess renal function (BUN, creatinine) as both hemolysis and rhabdomyolysis can cause acute kidney injury 1
• Check lactate dehydrogenase (LDH) and indirect bilirubin as markers of hemolysis
• Urinalysis to look for hemoglobinuria or myoglobinuria 1

Critical History Elements

• Recent oxidant drug exposure: dapsone, primaquine, sulfonamides, nitrofurantoin, rasburicase 1, 3, 4
• Fava bean ingestion (most common trigger causing 71.8% of major hemolysis cases) 5
• Recent infection (8.5% of hemolysis cases) 5
• Exercise history: Recent strenuous physical activity can trigger rhabdomyolysis in G6PD deficiency even without hemolysis 2
• Trauma history: Fall or injury mechanism 6

G6PD-Specific Considerations

Rhabdomyolysis Without Hemolysis

Recent evidence demonstrates that G6PD deficiency can cause severe rhabdomyolysis following routine exercise in the absence of hemolytic anemia 2. This atypical presentation means:

• Bilateral knee pain with elevated CK requires aggressive IV hydration
• Monitor for acute kidney injury development
• The absence of anemia does not exclude G6PD-related muscle injury

Bilateral Patellar Tendon Pathology

If the patient has end-stage renal disease (ESRD) comorbidity, there is documented association between G6PD deficiency, ESRD, and bilateral patellar tendon avulsion 6. Obtain:

• Plain radiographs of both knees (AP, lateral, Merchant views)
• MRI if clinical suspicion for tendon rupture (inability to extend knee, palpable defect, high-riding patella)

Management Algorithm

If Hemolysis or Rhabdomyolysis Present:

1. Aggressive IV hydration with normal saline to maintain urine output >200 mL/hour 2
2. Avoid methylene blue - it is contraindicated in G6PD deficiency and can worsen hemolysis 3
3. Use ascorbic acid (vitamin C) as alternative treatment: 0.5-2 g IV every 4-12 hours for hemolysis 3
4. Remove triggering agent immediately
5. Monitor hemoglobin and renal function closely
6. Consider exchange transfusion if severe hemolysis with methemoglobin >20% or refractory to treatment 3

If Standard Musculoskeletal Pathology:

Once G6PD-related complications are excluded:

• Evaluate for osteoarthritis with weight-bearing radiographs if age >50 and gradual onset 7
• Assess for inflammatory arthritis (ESR, CRP, rheumatoid factor, anti-CCP)
• Consider septic arthritis if fever, effusion, or systemic symptoms (joint aspiration)
• Evaluate for tendon pathology particularly if ESRD present 6

Critical Medication Avoidance

Absolutely contraindicated in G6PD deficiency 1, 3, 4:

• Methylene blue (can cause severe hemolysis)
• Rasburicase (contraindicated)
• Dapsone
• Primaquine
• Sulfonamides (though recent data suggests some may be safer than previously thought) 5

Generally safe medications based on real-world evidence 5:

• Nitrofurantoin (prescribed safely to 1,366 G6PD patients)
• Ciprofloxacin
• Sulfamethoxazole/cotrimoxazole (in many cases)

Common Pitfall

The bilateral presentation creates high risk of missing the diagnosis because there is no normal contralateral knee for comparison 6. Maintain high suspicion for both systemic G6PD complications and bilateral structural pathology, particularly in patients with ESRD.

The variant type matters: GdMed (Mediterranean variant) can cause life-threatening hemolysis, while GdA- (African variant) causes milder, self-limited hemolysis 1, 8. This influences treatment urgency and aggressiveness.